These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 28625004)

  • 21. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall.
    Stolk EA; van Donselaar G; Brouwer WB; Busschbach JJ
    Pharmacoeconomics; 2004; 22(17):1097-107. PubMed ID: 15612829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective.
    Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM
    Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lifetime QALY prioritarianism in priority setting: quantification of the inherent trade-off.
    Ottersen T; Mæstad O; Norheim OF
    Cost Eff Resour Alloc; 2014 Jan; 12(1):2. PubMed ID: 24418267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A flexible formula for incorporating distributive concerns into cost-effectiveness analyses: Priority weights.
    Haaland ØA; Lindemark F; Johansson KA
    PLoS One; 2019; 14(10):e0223866. PubMed ID: 31600342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality adjusted life years based on health and consumption: A summary wellbeing measure for cross-sectoral economic evaluation.
    Cookson R; Skarda I; Cotton-Barratt O; Adler M; Asaria M; Ord T
    Health Econ; 2021 Jan; 30(1):70-85. PubMed ID: 33094548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severity-Adjusted Probability of Being Cost Effective.
    Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
    Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs and expected gain in lifetime health from intensive care versus general ward care of 30,712 individual patients: a distribution-weighted cost-effectiveness analysis.
    Lindemark F; Haaland ØA; Kvåle R; Flaatten H; Norheim OF; Johansson KA
    Crit Care; 2017 Aug; 21(1):220. PubMed ID: 28830479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss.
    Hernæs UJV; Johansson KA; Ottersen T; Norheim OF
    Pharmacoeconomics; 2017 Sep; 35(9):965-974. PubMed ID: 28625004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL; Willis WD; Foos V
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On the role of cost-effectiveness thresholds in healthcare priority setting.
    Siverskog J; Henriksson M
    Int J Technol Assess Health Care; 2021 Jan; 37():e23. PubMed ID: 33491617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analyzing cost-effectiveness of ulnar and median nerve transfers to regain forearm flexion.
    Wali AR; Park CC; Brown JM; Mandeville R
    Neurosurg Focus; 2017 Mar; 42(3):E11. PubMed ID: 28245686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness.
    Baltussen R; Jansen MP; Mikkelsen E; Tromp N; Hontelez J; Bijlmakers L; Van der Wilt GJ
    Int J Health Policy Manag; 2016 Nov; 5(11):615-618. PubMed ID: 27801355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new proposal for priority setting in Norway: Open and fair.
    Ottersen T; Førde R; Kakad M; Kjellevold A; Melberg HO; Moen A; Ringard Å; Norheim OF
    Health Policy; 2016 Mar; 120(3):246-51. PubMed ID: 26851991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review.
    Jit M; Mibei W
    Vaccine; 2015 Jul; 33(32):3788-94. PubMed ID: 26144897
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.